Resolution of the phylogenetic position of the Congo peafowl, Afropavo congensis: a biogeographic and evolutionary enigma von Kimbal, Rebecca T., Brau, Edward L., David Ligon, J.

Volltext

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 von Naggie, Susanna, Cooper, Curtis, Saag, Michael, Workowski, Kimberly, Ruane, Peter, Towner, William J, Marks, Kristen, Luetkemeyer, Anne, Baden, Rachel P, Sax, Paul E, Gane, Edward, Santana-Bagur, Jorge, Stamm, Luisa M, Yang, Jenny C, German, Polina, Dvory-Sobol, Hadas, Ni, Liyun, Pang, Phillip S, McHutchison, John G, Stedman, Catherine A.M, Morales-Ramirez, Javier O, Bräu, Norbert, Jayaweera, Dushyantha, Colson, Amy E, Tebas, Pablo, Wong, David K, Dieterich, Douglas, Sulkowski, Mark

Volltext

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection von Foster, Graham R, Afdhal, Nezam, Roberts, Stuart K, Bräu, Norbert, Gane, Edward J, Pianko, Stephen, Lawitz, Eric, Thompson, Alex, Shiffman, Mitchell L, Cooper, Curtis, Towner, William J, Conway, Brian, Ruane, Peter, Bourlière, Marc, Asselah, Tarik, Berg, Thomas, Zeuzem, Stefan, Rosenberg, William, Agarwal, Kosh, Stedman, Catherine A.M, Mo, Hongmei, Dvory-Sobol, Hadas, Han, Lingling, Wang, Jing, McNally, John, Osinusi, Anu, Brainard, Diana M, McHutchison, John G, Mazzotta, Francesco, Tran, Tram T, Gordon, Stuart C, Patel, Keyur, Reau, Nancy, Mangia, Alessandra, Sulkowski, Mark

Volltext

SOF/VEL/VOX Results in High SVR12 Rates when Administered for 12 Weeks in Daa-Experienced Patients or for 8 Weeks in Daa-Naïve Patients: An Integrated Analysis of the POLARIS-1, PO... von Flamm, Steven L, Roberts, Stuart, Cooper, Curtis L, Lawitz, Eric, Reddy, K. Rajender, Thompson, Alexander, Zeuzem, Stefan, Jacobson, Ira M, Ruane, Peter J, Mehta, Swarup S, Hyland, Robert H, Stamm, Luisa, Han, Lingling, Brainard, Diana, Brau, Norbert, Asselah, Tarik, Willems, Bernard, Bourliere, Marc, Foster, Graham R, Gane, Edward, Manns, Michael, Gordon, Stuart C, Kowdley, Kris V

Volltext

424 - SOF/VEL/VOX Results in High SVR12 Rates when Administered for 12 Weeks in Daa-Experienced Patients or for 8 Weeks in Daa-Naïve Patients: An Integrated Analysis of the POLARIS... von Flamm, Steven L., Roberts, Stuart, Cooper, Curtis L., Lawitz, Eric, Reddy, K. Rajender, Thompson, Alexander, Zeuzem, Stefan, Jacobson, Ira M., Ruane, Peter J., Mehta, Swarup S., Hyland, Robert H., Stamm, Luisa, Han, Lingling, Brainard, Diana, Brau, Norbert, Asselah, Tarik, Willems, Bernard, Bourliere, Marc, Foster, Graham R., Gane, Edward, Manns, Michael, Gordon, Stuart C., Kowdley, Kris V.

Volltext

Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection von Poordad, Fred, Sievert, William, Mollison, Lindsay, Bennett, Michael, Tse, Edmund, Bräu, Norbert, Levin, James, Sepe, Thomas, Lee, Samuel S, Angus, Peter, Conway, Brian, Pol, Stanislas, Boyer, Nathalie, Bronowicki, Jean-Pierre, Jacobson, Ira, Muir, Andrew J, Reddy, K. Rajender, Tam, Edward, Ortiz-Lasanta, Grisell, de Lédinghen, Victor, Sulkowski, Mark, Boparai, Navdeep, McPhee, Fiona, Hughes, Eric, Swenson, E. Scott, Yin, Philip D

Volltext

P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies von Roberts, Stuart K., Cooper, Curtis L., Lawitz, Eric, Rajender Reddy, K., Thompson, Alex J., Zeuzem, Stefan, Jacobson, Ira M., Ruane, Peter, Hyland, Robert H., Stamm, Luisa M., Han, Lingling, Brainard, Diana M., Bräu, Norbert, Asselah, Tarik, Willems, Bernard E., Flamm, Steven, Bourlière, Marc, Foster, Graham R., Gane, Edward J., Manns, Michael, Gordon, Stuart C., Kowdley, Kris

Volltext